Business Model Breakdown
How Protalix Biotherapeutics Inc Makes Money
PLX
Market Cap
$167M
Annual Revenue
$53M
Profit Margin
-12.5%
Employees
213
The Short Version
Protalix Biotherapeutics is a biotechnology company that develops and sells plant-cell expressed recombinant therapeutic proteins primarily for rare genetic diseases. Their main revenue comes from two enzyme replacement therapies: Elfabrio for Fabry disease and Elelyso for Gaucher disease. Protalix partners with Chiesi Global Rare Diseases, which handles the global commercialization and distribution of these drugs. In return, Protalix receives a share of product sales and milestone payments tied to regulatory approvals and commercial achievements. Their unique ProCellEx manufacturing platform is key to producing their therapies.
Where the Revenue Comes From
Elfabrio product sales and milestone payments (~40-45% of 2026 projected revenue, excluding milestones)
Elelyso product sales (~25-30% of 2026 projected revenue)
Other revenue (e.g., R&D grants, other partnerships)
Who buys: Patients suffering from rare genetic diseases (e.g., Fabry, Gaucher) who require enzyme replacement therapy, prescribed by specialist physicians.
Why It Works (Competitive Advantages)
- ✔Proprietary ProCellEx plant-cell expression platform for enzyme production
- ✔Differentiated product profile (e.g., every-4-weeks dosing for Elfabrio)
- ✔Strong global commercialization partnership with Chiesi
Economic Moat: Narrow (Intangible Assets/IP (Proprietary ProCellEx platform, Elfabrio patents, orphan drug designations), Switching Costs (for patients on an established enzyme replacement therapy), Partnerships (Chiesi's global commercialization network))
What Our Analysis Says
DVR Score as of April 13, 2026
Protalix (PLX) maintains significant growth potential following the EU approval of Elfabrio's expanded dosing regimen and the triggered $25.0 million milestone, boosting projected cash to ~$50 million by April 2026. This, coupled with robust 2026 revenue guidance of $78–$83 million, strengthens its strategic market position in rare diseases. However, the FY 2025 TTM net loss of $6.6 million, a clear decline from Q3 TTM profit, and the substantial 20.79% stock drop on the news date, indicate underlying profitability challenges and negative market sentiment. While the proprietary ProCellEx platform and Chiesi partnership provide a competitive moat, sustained profitability and positive market reaction are critical for achieving the full 10x per-share growth potential.